598 related articles for article (PubMed ID: 15906777)
1. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
4. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
5. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C.
Younossi ZM; Mullen KD; Hodnick S; Barnes DS; Carey WD; McCullough AC; Easley K; Gramlich T; Liebermann BY
J Clin Gastroenterol; 2003; 36(5):427-30. PubMed ID: 12702987
[TBL] [Abstract][Full Text] [Related]
6. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
7. Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection.
Horsmans Y; Colle I; Van Vlierberghe H; Langlet P; Adler M; Bourgeois N; Brenard R; Michielsen P; Goossens A; Bruckers L;
Acta Gastroenterol Belg; 2008; 71(3):293-7. PubMed ID: 19198574
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
[TBL] [Abstract][Full Text] [Related]
9. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
Akhan SC; Gurel E; Sayan M
Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
[TBL] [Abstract][Full Text] [Related]
11. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
[TBL] [Abstract][Full Text] [Related]
12. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
Younossi ZM; Mullen KD; Zakko W; Hodnick S; Brand E; Barnes DS; Carey WD; McCullough AC; Easley K; Boparai N; Gramlich T
J Hepatol; 2001 Jan; 34(1):128-33. PubMed ID: 11211889
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Teuber G; Pascu M; Berg T; Lafrenz M; Pausch J; Kullmann F; Ramadori G; Arnold R; Weidenbach H; Musch E; Junge U; Wiedmann KH; Herrmann E; Zankel M; Zeuzem S
J Hepatol; 2003 Oct; 39(4):606-13. PubMed ID: 12971972
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL
Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
Poynard T; Colombo M; Bruix J; Schiff E; Terg R; Flamm S; Moreno-Otero R; Carrilho F; Schmidt W; Berg T; McGarrity T; Heathcote EJ; Gonçales F; Diago M; Craxi A; Silva M; Bedossa P; Mukhopadhyay P; Griffel L; Burroughs M; Brass C; Albrecht J;
Gastroenterology; 2009 May; 136(5):1618-28.e2. PubMed ID: 19208349
[TBL] [Abstract][Full Text] [Related]
17. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G;
Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
Alsaran K; Sabry A; Molhem A
Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
Kamal SM; El Kamary SS; Shardell MD; Hashem M; Ahmed IN; Muhammadi M; Sayed K; Moustafa A; Hakem SA; Ibrahiem A; Moniem M; Mansour H; Abdelaziz M
Hepatology; 2007 Dec; 46(6):1732-40. PubMed ID: 17943989
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]